Receptos Inc (NASDAQ:RCPT) To Present Radiance Study Data at MS Boston Conference

Boston, MA 09/11/2014 (wallstreetpr) – Receptos Inc (NASDAQ:RCPT) reported that data from Phase 2/3 trial study of RPC1063 will be reviewed during Oral Podium Presentation on September 13 at MS Boston 2014. It is a grand event where ACTRIMS and ECTRIMS are going to meet on the same platform. It will mark as the largest […]

Receptos Inc (NASDAQ:RCPT) Raising Funds For Product Development

Boston, MA 06/19/2014 (wallstreetpr) – Receptos Inc (NASDAQ:RCPT) has turned to equity offering to raise funds for the development of its lead drug candidate PRC1063 and others. The drug is going through Phase III trial after showing compelling results in its Phase II study. The treatment targets multiple sclerosis (MS). The company has announced offering of […]